Humanin
A mitochondria-derived peptide with cytoprotective properties, studied for neuroprotection, metabolic regulation, and anti-aging effects.
A peptide encoded inside a mitochondrial gene, found in 2001 by screening a cDNA library from the one brain region an Alzheimer's patient had kept intact. The biology is real and the receptors are identified — it binds FPRL1/FPR2 and a CNTFR/gp130/WSX-1 trimeric complex, blocks BAX, and declines with age, with the children of centenarians carrying notably higher levels. What does not exist is any human use: not one registered trial has ever given humanin or an analogue to a person, there is no human pharmacokinetic data, and the first mitochondrial-derived peptide to reach human testing was a MOTS-c analogue, not this one. Most published work uses HNG, a synthetic variant roughly a thousand times more potent — so the molecule in the studies is usually not the molecule being sold.
What is Humanin?
Humanin is a 24-amino acid peptide encoded within the mitochondrial genome. It was first discovered in 2001 during research into Alzheimer's disease and has since been studied for its broad cytoprotective effects. Humanin levels naturally decline with age, and supplementation is explored for neuroprotection, metabolic health, and longevity.
What Humanin Is Investigated For
Humanin is studied primarily as a mitochondrial-derived cytoprotective peptide with putative roles in neuroprotection (particularly against Alzheimer's pathology), insulin sensitivity, and protection against oxidative and apoptotic stress. The strongest evidence is mechanistic rather than clinical — BAX inhibition, IGFBP-3 binding, and STAT3 activation are well-characterized in cell and animal models, and observational human data show circulating Humanin declines with age and correlates with metabolic and cognitive parameters. What is essentially absent is interventional human data: no completed Phase II trials of exogenous Humanin for any indication, no established human pharmacokinetics, and no dose-ranging work. Most preclinical research uses the synthetic HNG (S14G) analog, which is ~1000-fold more potent than wild-type Humanin, so even the preclinical literature does not always translate cleanly to the 'Humanin' sold in research-chemical channels. The honest framing: interesting endogenous biology, unvalidated as a therapeutic.
History & Discovery
Humanin was described in 2001 in a series of papers from a single laboratory — Ikuo Nishimoto's group at Keio University, with Yuichi Hashimoto as first author on each. (This page previously described them as two independent groups; they are not, and the author lines of the PNAS, BBRC and Journal of Neuroscience papers all carry Hashimoto first and Nishimoto last.) The method is worth stating precisely because it is the memorable part: the team ran a functional expression screen on a cDNA library built from mRNA taken postmortem from the occipital lobe of an Alzheimer's patient — chosen because that region stays relatively intact in the disease — looking for anything that would rescue neurons from death caused by familial Alzheimer's genes and amyloid-beta. What came back was a short polypeptide they named Humanin. The peptide's defining genomic feature emerged from follow-up work: Humanin is a 24-amino-acid peptide encoded by a short open reading frame within the mitochondrial 16S rRNA gene. This was unusual — mitochondrial DNA had been thought to encode only a small defined set of proteins, and Humanin was among the earliest examples of a functionally active peptide emerging from the mitochondrial genome's non-canonical coding capacity. Humanin became the founding member of what Pinchas Cohen's laboratory at USC later termed the mitochondrial-derived peptides (MDPs) — a family that expanded to include MOTS-c, SHLP1–6, and others. Cohen's group has driven much of the subsequent rigorous mechanistic work on Humanin, tying it to IGFBP-3 binding, BAX inhibition, STAT3 activation, and age-related decline in circulating levels. The science is legitimate and reasonably well-characterized: Humanin is a real endogenous cytoprotective peptide with identifiable receptors and pathways. What the science does not yet support is clinical translation. There are no approved indications anywhere, no completed Phase II trials for any clinical endpoint, and almost no interventional human data with exogenous Humanin. The translational distance between 'interesting mitochondrial biology' and 'therapeutic product' is significant and currently unbridged. Much of the research-chemical and wellness-channel availability of Humanin analogs (HNG, S14G-humanin) is running well ahead of what the clinical evidence supports.
How It Works
Humanin acts as a cellular guardian, protecting cells from stress and programmed death. It communicates between mitochondria and the rest of the cell, helping maintain cellular health as we age.
Humanin exerts cytoprotective effects through several mechanisms, and unlike many research peptides it has identified receptors rather than an inferred mechanism. Extracellularly it engages the G-protein-coupled formyl peptide receptor-like 1 (FPRL1, also FPR2) and a trimeric receptor assembled from CNTFR-alpha, gp130 and WSX-1, which drives JAK2/STAT3 signalling. Intracellularly it binds BAX, preventing its translocation from cytosol to mitochondria and thereby blocking mitochondrial membrane permeabilization and apoptosis — 2026 structural work extends this to BID, showing humanin reduces both BAX- and truncated-BID-mediated membrane permeabilization. It also binds IGFBP-3, modulating IGF-1 signalling, and reduces amyloid-beta toxicity in neuronal cells. Reports that humanin improves insulin sensitivity are separate from reports that it activates AMPK: the insulin-sensitivity literature is reviewed without an AMPK mechanism, and the clearest AMPK result is in retinal pigment epithelium, where humanin activated AMPK leading to ULK1 and Beclin1 phosphorylation. No cited work joins the two, and this page previously implied it did. Recent 2026 work has broadened the cell-death-modality picture beyond apoptosis: Jang and colleagues (Aging Cell 2026) showed that Humanin drives AMPK–Beclin1-dependent mitophagy in retinal pigment epithelium under Aβ stress, and Liu and colleagues (Eur J Pharmacol 2026) reported that S14G-humanin (HNG) suppresses Z-DNA/ZBP1-mediated necroptosis in diabetic nephropathy tubular injury — extending the classical anti-apoptotic story into mitophagy and necroptosis regulation. A parallel 2026 preclinical thread from Wu and colleagues (Am J Respir Cell Mol Biol) and the companion Zingarelli review has opened a new indication direction: HNG protects septic ARDS via mitochondrial function in lung vascular endothelial cells, positioning Humanin as an emerging therapeutic candidate for acute respiratory distress syndrome. A kidney thread has firmed up alongside it: beyond the diabetic-nephropathy necroptosis work, Abueid and colleagues (Exp Physiol 2026) reported that HNG given before reperfusion attenuated oxidative stress, inflammation, and apoptosis and improved mitochondrial complex I activity and ATP in a rat renal ischemia-reperfusion model — though notably without improving blood urea nitrogen or serum creatinine, a candid reminder that organ-protective signaling markers and actual organ function do not always move together. In infection, Zhong and colleagues (Pathogens 2026) found serum humanin elevated in patients with hypervirulent Klebsiella pneumoniae infection relative to controls, and showed that humanin pretreatment in mice (2.5 or 5 mg/kg/day for five days) reduced liver injury and NF-κB activation, with the higher dose prolonging survival. Tanahashi and colleagues (Neuroscience 2026) add cell-level support for the anti-aging framing, reporting that chronic HNG treatment attenuated culture-induced senescence markers (SA-β-gal activity, Ki67, SASP factors) and preserved dopamine release in differentiated PC12 cells. The MTRNR2Lx paralog family framing (Shahzaib et al., Biomolecules 2026) provides the first systematic map of the humanin-like paralog family (MTRNR2L1–13) as the broader regulatory context.
Evidence Snapshot
Human Clinical Evidence
Observational only. Circulating humanin has been correlated with age, cardiovascular risk, diet, cancer and kidney disease, and one randomized hyperbaric-oxygen trial in vascular dementia found serum humanin rose alongside cognitive scores. But no registered interventional study has ever administered humanin or an analogue to a human being — every humanin trial on ClinicalTrials.gov is observational or tests a different agent with humanin as a readout. There is no human pharmacokinetic data, no dose-ranging work and no completed Phase II for any indication.
Animal / Preclinical
Extensive. Animal models demonstrate neuroprotection, improved metabolic function, and extended healthspan.
Mechanistic Rationale
Strong in outline, with real receptors identified: humanin binds the G-protein-coupled formyl peptide receptor-like 1 (FPRL1/FPR2) and a trimeric CNTFR-alpha/gp130/WSX-1 complex that drives JAK2/STAT3 signalling, alongside intracellular BAX interaction and IGFBP-3 binding. The STAT3 arm is not unidirectional — 2026 work reports humanin increasing STAT3 phosphorylation in renal ischaemia-reperfusion and suppressing STAT3 in septic lung endothelium — so pathway direction appears to be tissue- and context-dependent rather than fixed.
Research Gaps & Open Questions
What the current literature has not yet settled about Humanin:
- 01Human Phase II/III clinical trials for any indication — currently absent. The leap from well-characterized biology to clinical protocol has not been made.
- 02Human pharmacokinetics of exogenous Humanin and its analogs — absorption, distribution, clearance, and bioavailability by subcutaneous and other routes are not established.
- 03Dose-response in humans — no dose-finding studies; current forum dosing is rodent-extrapolated.
- 04Long-term safety, including cancer surveillance — the anti-apoptotic mechanism creates a specific theoretical cancer-risk question that has not been addressed by human pharmacovigilance.
- 05Efficacy of exogenous Humanin for specific endpoints (cognitive preservation, insulin sensitivity, cardiometabolic risk) in controlled human trials — not yet demonstrated.
- 06Comparative biology of Humanin versus its analogs (HNG, S14G-humanin) in humans — most preclinical work uses the analogs for potency reasons, and the extent to which wild-type Humanin produces comparable effects at achievable exogenous doses is unresolved.
- 07Whether exercise reliably raises circulating Humanin, and whether it matters. Acute endurance exercise raised plasma Humanin in one study and resistance training raised skeletal-muscle Humanin in another, but a 2026 Experimental Physiology study found little or no change after 45 minutes of running in adults with cerebral palsy or controls, and a 2026 systematic review of nine studies concluded that the evidence for exercise activating mitochondrial-derived peptides is limited. Whether any exercise-induced change is large enough, durable enough, or causally connected to a health outcome is unestablished.
- 08Whether Humanin's organ-protective signaling translates into preserved organ function. In a 2026 rat renal ischemia-reperfusion study, HNG improved oxidative-stress markers, mitochondrial complex I activity, apoptosis, and antioxidant capacity — but left blood urea nitrogen and serum creatinine unchanged. The gap between mechanistic markers and functional endpoints recurs across the Humanin preclinical literature.
- 09What rising endogenous Humanin during acute illness signifies. Serum Humanin is elevated in human hypervirulent Klebsiella infection and reduced in advanced chronic kidney disease, but whether a given level reflects protective compensation, disease severity, or neither is unknown — which complicates any attempt to interpret a Humanin blood level clinically.
Forms & Administration
Humanin analogs (such as HNG, the S14G variant) are more commonly studied due to enhanced potency and stability. Administration is typically subcutaneous injection in research settings. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
There is no established human therapeutic dose for Humanin or its analogs. Preclinical studies in rodents have used a broad range, typically 0.1–10 mg/kg, often with the more potent HNG (S14G-humanin) analog. Forum-described protocols for research-chemical Humanin or HNG typically use 2.5–10 mg per dose subcutaneously, though the basis for these numbers is essentially extrapolation from rodent studies without confirmed human PK or safety data.
Frequency
Forum protocols typically describe daily or every-other-day subcutaneous injection. There is no clinical frequency standard because there are no approved clinical protocols. Rodent studies have used a mix of daily dosing and intermittent protocols depending on the endpoint being studied.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Typical forum protocols cite 4–8 week courses, often with breaks. Chronic continuous use has not been studied in humans. Rodent studies that have reported extended-healthspan effects have used long-duration administration, but rodent duration does not translate directly to recommended human protocols.
Protocol Notes
Subcutaneous injection into abdominal fat is the most commonly described research-chemical route — and it is not the route the evidence was generated with. The published in-vivo work is overwhelmingly intraperitoneal, intravenous, intracerebroventricular or intranasal: the retinal-degeneration dose-ranging study used twice-weekly intraperitoneal injection, the Klebsiella liver-injury work intraperitoneal, the renal ischaemia-reperfusion work intravenous, the stroke neuroprotection work intracerebroventricular, and CNS-targeted studies have used intranasal delivery specifically to bypass the blood-brain barrier. Nobody has published a subcutaneous humanin study in any species, so the community route rests on convention rather than on data. Reconstitution is typically in bacteriostatic water from a lyophilized powder. HNG (S14G-humanin) is the analog most commonly sold because of its higher potency in preclinical assays (roughly 1000-fold more active than wild-type Humanin in some neuroprotection models) — this means labeled 'Humanin' product may in practice be an analog, and buyers should understand which molecule they are actually using. A candid observation: the evidence base for specific exogenous Humanin dosing in humans is essentially zero. Forum protocols are built on rodent dose conversions and theoretical mass-action reasoning. This is meaningfully different from peptides (Cerebrolysin, Selank, Semax) where approved international clinical protocols provide an anchor. Use of Humanin outside a formal research setting means operating without that anchor. Sourcing and purity are practical concerns. Humanin and HNG are 24-residue peptides that are more expensive to produce at purity than short peptides; product quality in the research-chemical channel varies substantially.
Humanin and its analogs are not FDA-approved or approved in any jurisdiction for any clinical indication. They are research tools, not therapeutic products. Any use outside a registered clinical research setting is not authorized medical care.
Timeline of Effects
Onset
No established onset profile in humans. Forum reports vary widely and include both subjective cognitive or energy changes within days and no noticeable acute effect. Cytoprotective and anti-apoptotic effects as demonstrated in cell and animal models would not produce obvious subjective acute signals in healthy users.
Peak Effect
Unknown in humans. Rodent endpoints (neuroprotection against Aβ toxicity, improved insulin sensitivity, protection against oxidative stress) are typically measured over days to weeks of dosing. Circulating Humanin levels in observational human studies correlate with metabolic and cognitive parameters over long time frames rather than acutely.
After Discontinuation
No documented withdrawal syndrome or rebound. Endogenous Humanin production continues regardless of exogenous administration, and exogenous peptide clearance is expected to be rapid. Any effects of exogenous dosing on structural endpoints (mitochondrial function, insulin sensitivity, neuronal protection) would likely fade over time proportional to the underlying biology, but human time-course data is not available.
Common Questions
How is Humanin related to MOTS-c?
Both Humanin and MOTS-c are mitochondrial-derived peptides (MDPs). While Humanin is primarily studied for neuroprotection and anti-apoptotic effects, MOTS-c is more focused on metabolic regulation and exercise mimetic properties.
Does exercise raise Humanin naturally?
Sometimes, modestly, and the evidence is weaker than it is usually presented. Acute endurance exercise has been reported to raise circulating mitochondrial-derived peptides including Humanin, and resistance training raised skeletal-muscle Humanin protein in men with impaired glucose metabolism. But a 2026 Experimental Physiology study found that 45 minutes of running produced no or only modest changes in circulating Humanin in adults and adolescents with cerebral palsy and in typically developing controls, and a 2026 systematic review of nine studies concluded the evidence that exercise activates these peptides is limited. The honest position is that exercise may nudge Humanin, that the nudge has not been shown to be durable, and that nobody has demonstrated the change itself produces a health benefit. Exercise is worth doing for reasons that do not depend on this peptide.
Is Humanin useful as a blood test or biomarker?
Not yet, and the direction of the signal is not consistent across conditions. Circulating Humanin declines with age, and observational work has linked it to cardiovascular risk prediction in chronic hemodialysis patients, Mediterranean diet adherence, and polycystic ovary syndrome. Advanced chronic kidney disease is associated with reduced mitochondrial-derived peptides, while acute hypervirulent Klebsiella infection is associated with elevated serum Humanin. That mix means a single Humanin value cannot currently be interpreted on its own: low may reflect age or chronic disease, high may reflect acute stress response. There is no validated reference range, no standardized assay across laboratories, and no clinical decision that should currently turn on a Humanin measurement.
Has humanin ever been given to a person?
No — and the answer is unusually clean for a research peptide. Every humanin study registered on ClinicalTrials.gov is either an observational biomarker study or an interventional trial of something else, with humanin measured as an outcome. Not one administers humanin or an analogue to a human being. There is no published human pharmacokinetic data, no dose-finding work, and no case report. The closest the mitochondrial-derived peptide class has come is CB4211, which completed a Phase 1a/1b with full pharmacokinetic endpoints in 88 subjects — but that is a MOTS-c analogue, not humanin, and it holds the distinction of being the first therapeutic candidate based on a mitochondrial-derived peptide to enter human testing. Anyone injecting humanin bought online is doing something no registered trial has ever done.
Do Humanin levels change with age?
Yes. Circulating Humanin levels decline significantly with age, which has led researchers to investigate whether supplementation could counteract age-related decline.
Who Humanin Is NOT For
- •Active or recent-history cancer — Humanin's anti-apoptotic activity (BAX inhibition) is mechanistically relevant to cancer cell survival; the theoretical concern that exogenous Humanin could support tumor cell survival has not been resolved by clinical data.
- •Pregnancy — no reproductive toxicology data; not recommended.
- •Breastfeeding — no data on transfer or effects on nursing infants.
- •Known hypersensitivity to synthetic peptides or to components used in reconstitution.
- •Pediatric use — no safety or developmental data in any pediatric population.
- •Concurrent use of therapies that depend on inducing apoptosis in target cells (certain chemotherapies, some experimental therapies) — theoretical mechanistic opposition.
Drug & Supplement Interactions
Clinical drug interactions for Humanin are undocumented because human pharmacology studies are absent. Theoretical interactions emerge from the known mechanisms. Humanin inhibits BAX-mediated apoptosis; concurrent use with pro-apoptotic cancer therapies (certain chemotherapeutic agents, radiation sensitizers) could in principle oppose therapeutic intent and should be avoided in oncology contexts. Humanin binds IGFBP-3 and modulates IGF-1 signaling; theoretical interactions with growth hormone therapy, IGF-1 axis drugs, and certain oncology agents targeting IGF signaling deserve clinician review. Humanin's reported insulin-sensitizing effects in preclinical models raise the theoretical possibility of additive effects with insulin, sulfonylureas, or GLP-1 agonists in diabetic patients — though clinical magnitude is unknown. The STAT3-pathway modulation introduces broad theoretical interaction surface with inflammation and immune modulation therapies, none of which has been clinically characterized. Patients on any regular medication — particularly insulin-dependent diabetics, oncology patients, and immunosuppressed individuals — should disclose Humanin use to their prescribing clinician. Combining with other peptides in longevity stacks (MOTS-c, SS-31, epithalon) is common in forum culture but has not been formally studied.
Safety Profile
Common Side Effects
Cautions
- • Not FDA-approved
- • Limited human dosing data
- • Endogenous peptide — exogenous effects may differ
What We Don't Know
Optimal dosing, long-term safety, and interactions with other therapies are not established in humans.
Legal Status
United States
Humanin and its analogs (HNG, S14G-humanin) are not FDA-approved for any indication. They are not recognized dietary supplement ingredients, not legal cosmetic ingredients, and do not have an established compounding pathway. Sold primarily through research-chemical suppliers not authorized for human use. Legal gray zone: not prohibited, but not approved through any legitimate clinical pathway.
International
Not approved as a medicine in Russia, the EU, UK, Australia, Canada, or any jurisdiction identified in public regulatory databases. Unlike Cerebrolysin or Selank, Humanin has no clinical regulatory approval anywhere. Availability internationally is through research-chemical channels subject to local rules.
Sports & Competition
Not listed by name on the WADA Prohibited List. Because it is not approved by any governmental health authority for human therapeutic use, it likely falls under WADA's S0 catch-all category prohibiting unapproved substances. Athletes subject to WADA code should assume it is prohibited and consult their national anti-doping authority.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Humanin is an FDA-approved longevity peptide.
Reality
Humanin is not FDA-approved for any indication, and it is not approved in any international regulatory jurisdiction. It is an endogenous peptide with interesting biology and legitimate academic research behind it, but it has no clinical product status.
Myth
Because Humanin is a naturally occurring peptide that declines with age, supplementing it must restore youthful function.
Reality
Age-associated decline in a biomarker does not automatically imply that restoring it will restore youthful function. Humanin's decline may be compensatory, epiphenomenal, or causally upstream of aging in ways we do not yet understand. Interventional human trials of exogenous Humanin for healthspan or lifespan endpoints have not been completed. Supplementation logic based on correlation is premature.
Myth
Humanin is a 24-amino-acid peptide, full stop.
Reality
Two forms exist and most descriptions give only one. A 24-residue peptide is found in the cytoplasm and a 21-residue variant appears to remain inside mitochondria; both share the same domains and both appear functional. The difference traces to where the open reading frame is translated — the mitochondrial ribosome and the cytosolic ribosome read the same MT-RNR2 sequence to different endpoints — and it is one reason the basic question of how humanin is transcribed and translated in vivo is still described in the literature as largely obscure.
Myth
Mouse studies of humanin are studies of humanin.
Reality
Often not in the way readers assume. In mice the humanin-encoding mitochondrial sequence is a pseudogene, and the humanin-like peptide is produced instead from a nuclear gene, Gm20594. So a great deal of rodent work is not reading the mitochondrial gene that defines humanin in humans at all. This compounds a separate problem the page already flags: most published in-vivo work uses the synthetic analogue HNG rather than wild-type humanin. Between the species difference and the analogue substitution, the molecule in a typical mouse paper may differ from the molecule in a vial twice over.
Myth
Humanin and HNG are interchangeable.
Reality
HNG (S14G-humanin) is a synthetic analog roughly 1000-fold more potent than wild-type Humanin in some preclinical neuroprotection assays. Using the two interchangeably without accounting for potency differences creates meaningful dosing discrepancies. Many published preclinical studies use HNG specifically; extrapolating those results to wild-type Humanin at the same mass dose is not valid.
Myth
Humanin is safe because it is naturally produced by the body.
Reality
Endogenous origin does not equal exogenous safety. Exogenous peptides can exceed physiological levels, act on non-primary receptors at higher concentrations, and produce effects not seen at normal circulating levels. The anti-apoptotic mechanism in particular raises specific theoretical concerns about tumor-cell survival that endogenous regulation does not permit at the concentrations exogenous dosing can produce.
Myth
Research-chemical Humanin delivers the doses reported in published studies.
Reality
Research-chemical-channel Humanin and HNG vary substantially in purity and actual peptide content. 24-residue peptides at high purity are expensive to produce, and independent testing of peptide products in this market has repeatedly found discrepancies between label and content. The extrapolation from 'published rodent dose' to 'consumer product dose' assumes content that is not independently verified.
Published Research
48 studiesHumanin attenuates neuronal cellular senescence and preserves neurotransmitter release in differentiated PC12 cells
Humanin Attenuates Inflammatory Liver Injury and NF-kB Activation During Systemic Hypervirulent Klebsiella pneumoniae Infection
S14G-humanin attenuates renal ischaemia-reperfusion injury, potentially through activation of STAT3 and ERK1/2 signalling pathways in rats
S14G-humanin in rat renal ischaemia-reperfusion, Exp Physiol 2026 — the clearest illustration on this page of markers moving without function following. HNG given before reperfusion improved oxidative-stress markers, mitochondrial complex I activity, ATP, apoptosis and antioxidant capacity, with increased STAT3 and ERK1/2 phosphorylation. Blood urea nitrogen and serum creatinine — the two measures of whether the kidney actually worked — were unchanged.
AGEs-RAGE Axis and Mitochondrial-Derived Peptides in Advanced Chronic Kidney Disease: Interconnected Pathways Beyond Inflammation and Nutrition
Mitochondrial-derived peptides (MDPs) activated by physical exercise as therapeutic targets for metabolic disorders: A systematic review
Network Topology and Interactomic Analysis Reveal the Regulatory Framework of the Humanin Protein Family (MTRNR2Lx Class)
S14G-humanin (HNG) ameliorates diabetic nephropathy tubular injury by inhibiting Z-DNA/ZBP1-mediated necroptosis
Circulating mitochondrial-derived microproteins at rest and in response to an acute bout of endurance exercise in individuals with cerebral palsy
Humanin Mitigates Aβ-Induced Retinal Pigment Epithelium Injury via AMPK-Beclin1-Dependent Mitophagy
Mitochondrial-derived Peptides and Cytoprotection in ARDS: Emerging Therapeutic Promise of Humanin
Humanin-G protects septic ARDS by mediating mitochondrial function in lung vascular endothelial cells
Humanin-G in septic ARDS, Am J Respir Cell Mol Biol 2026 — notable for two things the page would otherwise miss. It contains the only human kinetic curve available for humanin: in patients with septic ARDS, serum humanin rose markedly on day 1 and then fell progressively from day 3 to day 7. And its mechanism runs opposite to the page's general STAT3 story — the protective effect on mitochondria is attributed largely to suppression of STAT3 in septic lung endothelial cells, by inhibiting IL-6/STAT3 signalling, where other work reports humanin increasing STAT3 phosphorylation.
Mediterranean diet adherence is associated with mitochondrial microproteins Humanin and SHMOOSE; potential role of the Humanin-Nox2 interaction in cardioprotection
Circulating Humanin Improves the Prognostic Accuracy of Cardiovascular Risk Models in Chronic Hemodialysis Patients
Circulating humanin and cardiovascular risk in chronic hemodialysis patients — the result that should stop anyone treating a humanin level as a simple more-is-better readout. The association with cardiovascular and all-cause mortality was curvilinear: both low levels, below about 462 pg/mL, and high levels, above about 778 pg/mL, were linked to increased risk. A U-shaped relationship means the same value can be reassuring or alarming depending on which arm of the curve a patient sits on, and no reference range currently resolves that.
Redox-sensitive miRNAs and Humanin could mediate effects of exercise and astaxanthin on oxidative stress and inflammation in type 2 diabetes
Assessment of mitochondrial peptide humanin in women with polycystic ovary syndrome: serum and skeletal muscle profile
The neuroprotective role of Humanin in Alzheimer's disease: The molecular effects
A Review on the Potential Role of Humanin Peptide and its Analogs in the Regulation of Autophagy Pathways for Therapeutic Application in Metabolic Disorders
Impact of Radiation Therapy on Serum Humanin and MOTS-c Levels in Patients with Lung or Breast Cancer
Neuroprotective Action of Humanin and Humanin Analogues: Research Findings and Perspectives
Neuroprotective action of humanin and humanin analogues, 2023 — the source for two facts this page depends on. First the potency figure: HNG, in which the serine at position 14 is replaced by glycine, showed a 1000-fold higher neuroprotective activity than wild-type humanin, with a 500-fold higher rescue activity in cortical neurons exposed to a prion peptide. Second, and rarely mentioned: two intracellular forms exist, a 24-residue peptide in the cytoplasm and a 21-residue variant that stays within mitochondria, both apparently functional. The review also notes that in mice the humanin-encoding mitochondrial sequence is a pseudogene and the humanin-like peptide comes from a nuclear gene instead — which complicates reading mouse results as humanin results.
Neuron-derived extracellular vesicles in blood reveal effects of exercise in Alzheimer's disease
Humanin and Its Pathophysiological Roles in Aging: A Systematic Review.
Humanin and diabetes mellitus: A review of in vitro and in vivo studies
The Molecular Structure and Role of Humanin in Neural and Skeletal Diseases, and in Tissue Regeneration
Int J Mol Sci 2022 — the review that names the receptors, which this page previously failed to do anywhere. Humanin interacts with the G-protein-coupled formyl peptide receptor-like 1 (FPRL1/FPR2) and, separately, with a CNTFR-alpha/gp130/WSX-1 trimeric receptor complex that induces JAK2/STAT3 signalling. Which of the two routes carries which effect is unresolved, and that ambiguity is the central mechanistic gap in humanin biology.
Roles of humanin and derivatives on the pathology of neurodegenerative diseases and cognition
Cardio-protective role of Humanin in myocardial ischemia-reperfusion
The role of humanin in the regulation of reproduction
The role of humanin in natural stress tolerance: An underexplored therapeutic avenue
Humanin and Alzheimer's disease: The beginning of a new field
The emerging role of mitochondrial derived peptide humanin in the testis
Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans
Acute endurance exercise and circulating mitochondrial-derived peptides — frequently cited as evidence that exercise raises humanin, and more specific than that framing suggests. Circulating humanin was significantly elevated by acute endurance exercise but not by resistance exercise. Modality matters, the effect is acute rather than demonstrated to be durable, and no study has shown that the change itself produces a health benefit.
Humanin: A mitochondrial-derived peptide in the treatment of apoptosis-related diseases
Mechanisms of protection of retinal pigment epithelial cells from oxidant injury by humanin and other mitochondrial-derived peptides: Implications for age-related macular degeneration
Role of humanin, a mitochondrial-derived peptide, in cardiovascular disorders
The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan
Yen, Cohen and colleagues, Aging 2020 — the strongest human longevity data humanin has, and worth reading before accepting or dismissing the anti-ageing framing. Circulating humanin falls with age across species, but in the children of centenarians, who are themselves more likely to reach very old age, levels are much greater than in age-matched controls. Levels are also strikingly stable in the naked mole-rat, a model of negligible senescence, and decreased in Alzheimer's disease and MELAS. Note the competing interest: two authors are consultants and stockholders in a company commercialising mitochondrial-derived peptides.
Protective Effect of Hyperbaric Oxygen Therapy on Cognitive Function in Patients with Vascular Dementia
Epigenome-Wide Association Study Indicates Hypomethylation of MTRNR2L8 in Large-Artery Atherosclerosis Stroke
Mitochondrial-derived peptide humanin as therapeutic target in cancer and degenerative diseases
Mitochondrial-derived peptide humanin as therapeutic target in cancer and degenerative diseases — the honest version of this page's cancer caution. Rather than describing the oncological concern as purely theoretical, the authors write that the controversy over humanin's role in cancer progression and chemoresistance should be addressed before any of these therapeutic approaches are translated. A peptide whose signature action is blocking BAX-mediated apoptosis has an unresolved question about tumour-cell survival, not a hypothetical one.
Humanin G (HNG) protects age-related macular degeneration (AMD) transmitochondrial ARPE-19 cybrids from mitochondrial and cellular damage
Endoplasmic reticulum-mitochondrial crosstalk: a novel role for the mitochondrial peptide humanin
Humanin skeletal muscle protein levels increase after resistance training in men with impaired glucose metabolism
Humanin: Functional Interfaces with IGF-I
Potential Roles of Humanin on Apoptosis in the Heart
Humanin and age-related diseases: a new link?
Protective effects of Humanin and calmodulin-like skin protein in Alzheimer's disease and broad range of abnormalities
Humanin: a harbinger of mitochondrial-derived peptides?
Humanin is a novel neuroprotective agent against stroke
Humanin peptide suppresses apoptosis by interfering with Bax activation
Guo, Reed and colleagues, Nature 2003 — the mechanism that anchors every cytoprotection claim on this page. BAX, the pro-apoptotic protein that permeabilises mitochondria, interacts directly with humanin, and humanin prevents BAX translocating from cytosol to mitochondria. The anti-apoptotic action is therefore a protein-protein interaction rather than a receptor effect, which is also the root of the page's cancer caution: a peptide that blocks BAX blocks a route tumour cells are supposed to die by.
A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta.
Hashimoto, Niikura and colleagues in Ikuo Nishimoto's laboratory, PNAS 2001 — the discovery paper, and until this revision it was missing from a reference list of forty-seven. Through functional expression screening of a cDNA library they identified a gene they designated Humanin, encoding a short polypeptide that abolished the death of neuronal cells caused by multiple familial Alzheimer's disease genes and by amyloid-beta, while having no effect on death caused by Q79 or superoxide-dismutase-1 mutants. The rescue action depended on the peptide's primary structure, and the transfected cDNA was transcribed and then secreted into the culture medium — the first hint that this was a signalling molecule rather than an intracellular curiosity.
Quick Facts
- Class
- Mitochondrial-Derived Peptide
- Tier
- D
- Evidence
- Emerging
- Safety
- Limited Data
- Updated
- Nov 2026
- Citations
- 48PubMed
Also known as
Tags
Related Goals
Conditions Discussed
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.